AstraZeneca reported Q3 revenue of $16.21 billion and core EPS of $2.79, beating expectations. The company announced a restructuring plan targeting $1.5 billion in annual savings to fund its drug pipeline.

Read the original on AstraZeneca shares jump 7% after beating Q3 estimates. For more crypto news and analysis, visit TheCurrencyAnalytics.com.